Affinage

HOXB7

Homeobox protein Hox-B7 · UniProt P09629

Length
217 aa
Mass
24.0 kDa
Annotated
2026-06-10
94 papers in source corpus 33 papers cited in narrative 34 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 7/8 claims corpus-supported (88%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

HOXB7 is a homeodomain transcription factor that acts as an oncogenic master regulator of growth-factor signaling, angiogenesis, and epithelial-mesenchymal transition, while also fulfilling a developmental patterning role in the Hox cluster (PMID:8756643, PMID:17018609, PMID:9784603). Its founding activity is direct transactivation of the bFGF gene through homeodomain binding to its promoter, an axis required for melanoma proliferation and driving downstream Ras/RhoA/MAPK signaling and EMT in epithelial cells (PMID:8756643, PMID:9681827, PMID:17018609). HOXB7 directly binds and activates a broad set of oncogenic promoters, including EGFR (conferring tamoxifen resistance), TGFβ2 (promoting invasion and M2 macrophage recruitment), and miR-221/222, and its genome-wide binding sites have been mapped by ChIP-seq in breast cancer chromatin (PMID:21690342, PMID:25542862, PMID:23400877, PMID:26014856). Beyond transcription, HOXB7 coordinates the tumor angiogenic switch by upregulating VEGF-A, IL-8, MMP-9, and angiopoietin-2 (PMID:11522651), and stimulates DNA double-strand break repair by physically associating with the NHEJ machinery Ku70/Ku80/DNA-PKcs through its homeodomain (PMID:17308091, PMID:31568655). Its transcriptional output is tuned by protein partners: CBP and IκB-α enhance its activity, while PARP-1 binds the homeodomain and poly(ADP-ribosyl)ates the C-terminal glutamate-rich tail to suppress DNA binding (PMID:10435624, PMID:10026139, PMID:22844406). Full oncogenic activity requires TALE cofactors PBX2/PREP1 acting as dimerization partners (PMID:18378073, PMID:23400877), and HOXB7 additionally forms a complex with ERα to activate ERα/HER2 target genes (PMID:26180042). A non-transcriptional cytoplasmic role localizes HOXB7 to cell protrusions where it stimulates ERK1/2 phosphorylation to remodel actin and drive motility (PMID:28912272). In development, Hoxb7 patterns the upper thoracic skeleton in functional cooperation with the paralog Hoxa7 (PMID:9784603).

Mechanistic history

Synthesis pass · year-by-year structured walk · 30 steps
  1. 1993 Medium

    Before its biochemical activity was known, the question was how Hoxb-7 achieves its spatially restricted expression; cis-regulatory dissection established that clustered Hox control elements direct its anterior-posterior boundaries.

    Evidence Transgenic mouse promoter-reporter deletion analysis with in situ hybridization

    PMID:8104144

    Open questions at the time
    • Trans-acting factors binding these elements not identified here
    • Does not address protein function
  2. 1996 High

    The first direct molecular function was established by showing HOXB7 binds and transactivates the bFGF promoter, linking a homeodomain factor to a defined growth-factor target driving proliferation.

    Evidence EMSA, cotransfection reporter assay, and antisense knockdown in melanoma cells

    PMID:8756643

    Open questions at the time
    • Other direct targets not yet mapped
    • In vivo relevance not tested
  3. 1998 High

    Gain-of-function in breast carcinoma cells confirmed bFGF as a functional downstream effector, establishing HOXB7 as a transforming factor that confers anchorage-independent growth and serum independence.

    Evidence Retroviral transduction of SkBr3 cells, ELISA, antisense, colony formation

    PMID:9681827

    Open questions at the time
    • bFGF-independent functions not addressed
    • Cofactor requirements unknown
  4. 1998 High

    The question of whether HOXB7 has an endogenous developmental role was answered by double-mutant genetics showing it patterns the thoracic skeleton cooperatively with its paralog Hoxa7.

    Evidence Hoxa7/Hoxb7 knockout mice with skeletal phenotyping

    PMID:9784603

    Open questions at the time
    • Molecular targets in skeletal patterning unidentified
    • Relationship to oncogenic targets unexplored
  5. 1999 Medium

    To explain how HOXB7 transactivation is potentiated, protein partners were sought; CBP and IκB-α were shown to bind the HOXB7 N-terminus and enhance its transcriptional output, with acetylation implicated as a regulatory layer.

    Evidence Co-IP/in vitro binding, domain-mapping mutagenesis, reporter assays, TSA treatment

    PMID:10026139 PMID:10435624

    Open questions at the time
    • IκB-α interaction shown in vitro only
    • Endogenous stoichiometry and target-gene specificity not defined
  6. 1999 Medium

    Whether HOXB7 affects normal cell fate was tested in hematopoietic progenitors, showing it stimulates progenitor proliferation and myeloid-restricted differentiation.

    Evidence Retroviral transduction of human HPCs/HSCs with clonogenic and LTC-IC assays

    PMID:10208421

    Open questions at the time
    • Transcriptional targets in hematopoiesis unidentified
    • Single lab
  7. 2001 High

    The mechanism by which HOXB7 promotes tumor vascularization was defined by showing it coordinately upregulates multiple proangiogenic factors and yields highly vascularized xenografts, identifying it as a regulator of the angiogenic switch.

    Evidence Retroviral transduction, expression profiling, endothelial coculture, in vivo xenograft with CD31/CD34 staining

    PMID:11522651

    Open questions at the time
    • Direct promoter binding to angiogenic genes not all shown
    • Relative contribution of each target unresolved
  8. 2001 High

    Structure-function mapping defined which HOXB7 domains drive versus restrain its activity, including the Pbx-binding pentapeptide and homeodomain as positive elements and the glutamate-rich C-terminus as a negative regulator.

    Evidence Systematic mutagenesis in 32D myeloid cells with G-CSF differentiation readout

    PMID:11290787

    Open questions at the time
    • Biochemical basis of negative regulation by C-terminus not yet explained
    • Phosphorylation site function inferred indirectly
  9. 2003 High

    The upstream control of HOXB7 levels was clarified by identifying the transcription factors that activate its promoter, defining the regulatory inputs that set HOXB7 expression.

    Evidence Site-specific mutagenesis, reporter assays, and EMSA across a 1.9-kb promoter

    PMID:12697323

    Open questions at the time
    • Context-specific use of these sites in cancer not tested
    • Chromatin-level regulation not addressed
  10. 2006 High

    The cellular consequence of HOXB7 activity was elevated from proliferation to EMT, showing HOXB7 drives mesenchymal conversion through a bFGF/Ras/RhoA/MAPK cascade reversible by pathway inhibitors.

    Evidence Gain-of-function in MCF10A/MDCK, immunofluorescence, GTPase pull-downs, pharmacological and siRNA rescue, xenograft

    PMID:17018609

    Open questions at the time
    • Direct transcriptional targets of EMT beyond bFGF not mapped
    • Reversibility in vivo not addressed
  11. 2007 High

    A transcription-independent function was uncovered by showing HOXB7 binds the Ku70/Ku80/DNA-PKcs/PARP machinery and enhances NHEJ, recasting it as a regulator of DNA double-strand break repair.

    Evidence GST pull-down, co-IP, NHEJ repair assays, siRNA knockdown

    PMID:17308091

    Open questions at the time
    • Whether HOXB7 acts catalytically or as a scaffold unresolved
    • Effect on repair fidelity not measured
  12. 2008 Medium

    The cofactor requirement for oncogenicity was tested, demonstrating HOXB7 oncogenic activity depends on TALE partners by modulating Pbx2/Prep1/Pbx1 balance.

    Evidence Dominant-negative Pbx1 expression, invasion/proliferation assays, xenograft, flow cytometry

    PMID:18378073

    Open questions at the time
    • Direct HOXB7-PBX2 binding not biochemically shown here
    • Target genes dependent on TALE cofactors not mapped
  13. 2008 High

    The in vivo role in HER-2/neu mammary tumorigenesis was defined as context-dependent, with Hoxb7 delaying onset but accelerating growth and metastasis.

    Evidence MMTV-Hoxb7 × MMTV-HER-2/neu double-transgenic mice with tumor and metastasis monitoring

    PMID:18463397

    Open questions at the time
    • Molecular basis of the dual phenotype unresolved
    • Stage-specific effectors not identified
  14. 2010 Medium

    Upstream miRNA control was integrated with downstream signaling, defining a miR-196a→HOXB7→bFGF→Ets-1→BMP4 cascade governing melanoma migration.

    Evidence miRNA gain/loss-of-function, reporter and migration assays, pharmacological inhibition

    PMID:20480203

    Open questions at the time
    • Direct vs indirect steps not all shown
    • Single lineage tested
  15. 2011 High

    A clinically relevant direct target was identified by showing HOXB7 binds the EGFR promoter to confer tamoxifen resistance, linking HOXB7 to acquired endocrine resistance.

    Evidence ChIP, luciferase reporter, gain-of-function, tamoxifen resistance assay

    PMID:21690342

    Open questions at the time
    • Feedback between EGFR and HOXB7 not fully resolved
    • In vivo resistance not tested here
  16. 2012 High

    Post-translational regulation was established by showing PARP-1 poly(ADP-ribosyl)ates the HOXB7 C-terminal tail to suppress DNA binding, explaining the negative role of that domain.

    Evidence Co-IP, GST pull-down, in vitro ADP-ribosylation, deletion mutagenesis, reporter and EMSA

    PMID:22844406

    Open questions at the time
    • Physiological triggers of PARylation unknown
    • Genome-wide effect on binding not measured
  17. 2012 Low

    An unexpected virus-host link was found in which HoxB7 associates with adenovirus E4orf6 and activates adenoviral promoters, broadening its transcriptional repertoire.

    Evidence Yeast two-hybrid, knockdown, viral replication and promoter assays

    PMID:22553335

    Open questions at the time
    • Interaction by yeast two-hybrid not confirmed in mammalian cells
    • Relevance to endogenous biology unclear
  18. 2013 Medium

    The HOXB7/PBX2 dimer was shown to directly drive oncogenic miR-221/222 transcription, and disrupting the dimer triggered cell death, validating dimerization as a vulnerability.

    Evidence HXR9 peptide antagonist, miRNA and reporter assays, apoptosis assay

    PMID:23400877

    Open questions at the time
    • Direct dimer binding to miR-221/222 promoter not shown by ChIP
    • Single melanoma context
  19. 2014 High

    A non-cell-autonomous metastatic mechanism was defined by showing HOXB7 directly activates TGFβ2 to drive invasion and recruit M2 macrophages.

    Evidence ChIP, luciferase, siRNA, pharmacological inhibition, lung metastasis model, macrophage coculture

    PMID:25542862

    Open questions at the time
    • Other tumor-microenvironment effectors not mapped
    • Direct vs paracrine contributions not fully separated
  20. 2015 Medium

    Genome-wide HOXB7 chromatin occupancy was mapped, expanding the direct target catalog beyond candidate genes.

    Evidence ChIP-seq with ChIP-qPCR validation and expression analysis in breast cancer cells

    PMID:26014856

    Open questions at the time
    • Target assignment by proximity, not functional assay
    • Cell-line-specific binding generality untested
  21. 2015 High

    An ERα-cofactor function was established by showing HOXB7 forms a complex with ERα to activate ERα/HER2 targets within a MYC→miR-196a→HOXB7→ERα-HER2 axis.

    Evidence ChIP, co-IP, reporter, MYC inhibitors, xenograft regression

    PMID:26180042

    Open questions at the time
    • Structural basis of HOXB7-ERα complex unknown
    • Generality across ER+ subtypes untested
  22. 2015 Medium

    A non-malignant regulatory role was confirmed in mesenchymal stem cells, where HOXB7 sustains proliferation and osteogenesis via autocrine bFGF, extending the bFGF axis to stem-cell aging.

    Evidence Forced expression, proliferation/senescence/osteogenic assays, bFGF ELISA

    PMID:25428821

    Open questions at the time
    • Direct targets in MSCs beyond bFGF unidentified
    • Single lab
  23. 2016 Medium

    A cytoplasmic, non-transcriptional function was demonstrated by localizing HOXB7 to cell protrusions where it stimulates ERK1/2 to remodel actin and drive motility.

    Evidence siRNA knockdown with rescue, immunocytochemistry, phosphoprotein Western blots, motility assays in pancreatic cancer cells

    PMID:28912272

    Open questions at the time
    • Mechanism of ERK activation by cytoplasmic HOXB7 unknown
    • Direct partners in protrusions unidentified
  24. 2016 Medium

    A direct interaction with β-catenin was found, linking HOXB7 to Wnt/β-catenin signaling to promote squamous carcinoma invasion and survival.

    Evidence Co-IP, siRNA knockdown, transwell assay, xenograft

    PMID:30067384

    Open questions at the time
    • Whether β-catenin alters HOXB7 transcriptional output or vice versa unresolved
    • Direct vs indirect target genes unclear
  25. 2016 Medium

    The interplay of HOXB7-driven DNA repair with antagonists was clarified by showing Cdx2 forms a complex with HoxB7 to block its chromatin recognition and dampen repair.

    Evidence Co-IP, etoposide DNA repair assay, domain deletion in colon cancer cells

    PMID:26902420

    Open questions at the time
    • Generality of Cdx2 antagonism beyond colon untested
    • Structural basis of competition unknown
  26. 2019 Medium

    The HOXB7-NHEJ axis was independently replicated and extended to chemoresistance, showing HOXB7 supports Ku/DNA-PKcs expression and cisplatin resistance in esophageal carcinoma.

    Evidence GST pull-down, co-IP, colocalization, siRNA, cisplatin sensitivity, HXR9 treatment

    PMID:31568655

    Open questions at the time
    • Whether HOXB7 transcriptionally controls Ku/DNA-PKcs or acts post-translationally not resolved
    • Single tumor type
  27. 2020 Medium

    The HOXB7-β-catenin complex was extended to stem-cell lineage choice, showing a miR-24/HOXB7/β-catenin axis balances osteogenesis and adipogenesis.

    Evidence Immunoprecipitation, miRNA gain/loss, luciferase, differentiation assays, calvarial defect model

    PMID:32413244

    Open questions at the time
    • Direct target genes of the complex in MSCs unmapped
    • Single lab
  28. 2021 Medium

    An epigenetic mode of EMT control was defined, showing HOXB7 silences CDH1 via DNMT3B-mediated promoter methylation, with ChIP confirming occupancy at multiple oncogenic loci.

    Evidence siRNA knockdown, bisulfite sequencing, ChIP-qPCR in TNBC cells

    PMID:34680970

    Open questions at the time
    • Whether DNMT3B is a direct HOXB7 target gene not fully resolved
    • Single TNBC line
  29. 2023 Medium

    A new downstream transforming pathway was identified, showing HOXB7 drives transformation and metastasis through JAK-STAT activation.

    Evidence Gain-of-function in NMuMG cells, transformation and metastasis assays, pathway analysis

    PMID:36659836

    Open questions at the time
    • Direct link between HOXB7 transcription and JAK-STAT activation unestablished
    • Single model
  30. 2024 Medium

    An immune-evasion mechanism was defined, showing HOXB7 suppresses tumor HLA class II via MAPK signaling and limits CD4+ T cell IFN-γ responses.

    Evidence siRNA knockdown, phospho-MAPK Western blot, HLA-II flow cytometry, T cell cytokine assay, MAPK inhibitor

    PMID:36285482

    Open questions at the time
    • Direct transcriptional targets bridging HOXB7 and MAPK unidentified
    • Single lab

Open questions

Synthesis pass · forward-looking unresolved questions
  • How HOXB7 partitions between its nuclear transcriptional, chromatin-modifying, DNA-repair, and cytoplasmic actin-remodeling roles within a single cell, and what governs this switch, remains unresolved.
  • No structural model of HOXB7 cofactor complexes
  • Determinants of nuclear vs cytoplasmic localization unknown
  • Regulatory logic integrating its multiple functions undefined

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0140110 transcription regulator activity 6 GO:0003677 DNA binding 4 GO:0060089 molecular transducer activity 1
Localization
GO:0005634 nucleus 4 GO:0005829 cytosol 2 GO:0005856 cytoskeleton 2
Pathway
R-HSA-1643685 Disease 5 R-HSA-74160 Gene expression (Transcription) 5 R-HSA-162582 Signal Transduction 4 R-HSA-1266738 Developmental Biology 3 R-HSA-73894 DNA Repair 3
Partners
CBPCTNNB1ESR1NFKBIAPARP1PRKDCXRCC5XRCC6
Complex memberships
DNA-PK holoenzyme (Ku70/Ku80/DNA-PKcs)HOXB7/ERα complexHOXB7/PBX2 dimer

Evidence

Reading pass · 34 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
1996 HOXB7 directly transactivates the bFGF (basic fibroblast growth factor) gene by binding to one of five putative homeodomain binding sites in its promoter, as demonstrated by band-shift (EMSA) and cotransfection assays; antisense oligomers targeting HOXB7 mRNA abolished bFGF expression and inhibited melanoma cell proliferation. EMSA (band-shift assay), cotransfection/reporter assay, antisense oligonucleotide knockdown Molecular and cellular biology High 8756643
1998 Transduction of HOXB7 into SkBr3 breast carcinoma cells (negative for both HOXB7 and bFGF) induced bFGF expression, increased cell proliferation, reduced serum dependence, and enabled anchorage-independent growth; antisense oligomers to bFGF inhibited growth in low-serum conditions, confirming bFGF as a functional downstream target of HOXB7. Retroviral gene transduction, ELISA, antisense oligonucleotide inhibition, colony formation assay Oncogene High 9681827
1999 HOXB7 physically interacted with the coactivator CBP (CREB-binding protein) both in vitro and in vivo; this interaction required the N-terminal domain of HOXB7 and two C-terminal domains of CBP, and enhanced HOXB7 transactivation potential. Histone deacetylase inhibition (trichostatin A) further enhanced HOXB7 transcriptional activity, implicating acetylation/deacetylation in regulation of HOXB7 function. Co-immunoprecipitation (in vivo), in vitro binding assay, deletion mutagenesis, transient transfection reporter assay, pharmacological inhibition (TSA) Oncogene High 10435624
1999 HOXB7 physically interacted in vitro with IκB-α; this interaction was mediated by IκB-α ankyrin repeats and C-terminal domain, and the HOXB7 N-terminal domain. IκB-α markedly increased HOXB7-dependent transcription from a reporter plasmid containing a homeodomain consensus-binding sequence, revealing a novel role for IκB-α as a positive regulator of HOX transcriptional activity. In vitro binding assay, transient transfection reporter assay, deletion mutagenesis The Journal of biological chemistry Medium 10026139
1999 Enforced expression of HOXB7 in human hematopoietic progenitor/stem cells (HPCs/HSCs) stimulated proliferation of primitive HPC and HSC subsets, expanded granulo-monocytic progenitors and their progeny, and promoted myeloid-restricted differentiation with sustained blast cell proliferation, suggesting a role in myeloid lineage commitment. Retroviral transduction into purified human HPCs/HSCs, HPP-CFC assay, LTC-IC assay, clonogenic assay, liquid suspension culture Oncogene Medium 10208421
2001 HOXB7 transduction into SkBr3 cells upregulated VEGF-A, GROα/MGSA, IL-8, angiopoietin-2, and MMP-9, while abrogating angiopoietin-1; HOXB7-transduced cells formed highly vascularized tumors in nude mice with increased CD31/CD34-positive vessels, establishing HOXB7 as a key regulator of the tumor angiogenic switch through multiple proangiogenic targets. Retroviral transduction, expression profiling, in vitro endothelial coculture/3D matrix assay, in vivo xenograft with CD31/CD34 immunostaining Cancer research High 11522651
2001 Functional regions of HOXB7 critical for inhibiting myeloid differentiation of 32D cells include the Pbx-binding pentapeptide motif, the DNA-binding homeodomain, and internal N-terminal sequences. Conversely, mutations eliminating casein kinase II target sites, the glutamate-rich C-terminus, or the first 14 amino acids led to enhanced differentiation, indicating these domains negatively regulate HOXB7 activity. Site-directed mutagenesis, deletion constructs, retroviral transduction into 32D myeloid cells, G-CSF-induced differentiation assay Journal of immunology High 11290787
2003 The HOXB7 promoter is regulated by direct binding of transcription factors NF-Y, YY1, Sp1/Sp3, and USF-1 to specific sites in a 1.9-kb 5' region; site-specific mutagenesis of these binding sites reduced HOXB7 gene expression by 55–78%, demonstrating functional necessity of these regulatory elements. Site-specific mutagenesis, cell transfection, reporter assay, electrophoretic mobility shift assay (EMSA) Biochimica et biophysica acta High 12697323
2006 Ectopic expression of HOXB7 in MCF10A and MDCK epithelial cells induced epithelial-mesenchymal transition (EMT), characterized by loss of claudin 1, claudin 7, mislocalization of claudin 4 and E-cadherin, and gain of vimentin and α-smooth muscle actin. HOXB7 upregulated bFGF, activated Ras and RhoA, and increased phosphorylation of ERK1/2; effects were reversed by FGF receptor inhibitors, Ras-MAPK inhibitors, and HOXB7-specific siRNA. Gain-of-function expression in epithelial cell lines, immunofluorescence, Western blot, GTP-Ras/RhoA pull-down assay, pharmacological inhibition, siRNA knockdown, in vivo xenograft Cancer research High 17018609
2007 HOXB7 interacts with the DNA-dependent protein kinase holoenzyme components Ku70, Ku80, and DNA-PKcs, as well as PARP, identified by GST pull-down/affinity chromatography and confirmed by co-immunoprecipitation in vivo. HOXB7 expression enhanced non-homologous end-joining (NHEJ) DNA repair in vitro and in vivo; silencing HOXB7 reversed these effects, establishing HOXB7 as a novel regulator of DNA double-strand break repair. GST pull-down/affinity chromatography, co-immunoprecipitation, NHEJ repair assay in vitro and in vivo, siRNA knockdown Cancer research High 17308091
2008 In SkBr3/HOXB7 cells, HoxB7 regulates expression of TALE cofactors by increasing Pbx2 and Prep1 and decreasing Pbx1. A dominant-negative Pbx1 mutant (Pbx1NT) that sequesters Prep1 in the cytoplasm reduced the oncogenic activity of HoxB7 (less aggressive phenotype, increased apoptosis, decreased cycling, upregulation of p16 and p53), demonstrating functional requirement of HOX-TALE cofactor interaction for HOXB7 oncogenic activity. Retroviral transduction, dominant-negative mutant expression, in vitro invasion/proliferation assay, in vivo xenograft, flow cytometry, Western blot Cancer letters Medium 18378073
2008 In MMTV-Hoxb7/HER-2/neu double-transgenic mice, Hoxb7 played a dual role: it delayed mammary tumor onset and reduced multiplicity, but accelerated tumor growth rate and increased lung metastasis frequency once tumors appeared, demonstrating context-dependent modulation of HER-2/neu-driven mammary tumorigenesis by Hoxb7 in vivo. Generation of MMTV-Hoxb7 transgenic mice, crossing with MMTV-HER-2/neu transgenic mice, tumor monitoring, lung metastasis analysis Cancer research High 18463397
2010 Loss of miR-196a expression in melanoma cells leads to increased HOXB7 mRNA and protein levels, which subsequently elevate Ets-1 activity by inducing bFGF; Ets-1 then induces BMP4 expression. BMP4 was identified as the major mediator of bFGF-induced migration in melanoma cells, establishing a miR-196a→HOXB7→bFGF→Ets-1→BMP4 signaling cascade. miRNA overexpression/knockdown, Western blot, reporter assay, migration assay, pharmacological inhibition Cellular and molecular life sciences Medium 20480203
2011 HOXB7 overexpression in MCF-7 cells rendered them resistant to tamoxifen by upregulating EGFR through direct binding of HOXB7 to the EGFR promoter, enhancing transcriptional activity. Extended tamoxifen treatment progressively increased HOXB7 and EGFR expression, establishing a mechanistic link between HOXB7, EGFR upregulation, and acquired endocrine resistance. Chromatin immunoprecipitation (ChIP), luciferase reporter assay, gain-of-function overexpression, Western blot, tamoxifen resistance assay Proceedings of the National Academy of Sciences of the United States of America High 21690342
2012 PARP-1 interacts with HOXB7 through the homeodomain of HOXB7 and the first zinc finger of PARP-1; upon binding, PARP-1 poly(ADP-ribosyl)ates HOXB7, reducing its transcriptional activity. Deletion of the evolutionarily conserved C-terminal glutamate-rich tail of HOXB7 dramatically attenuated ADP-ribosylation and rendered HOXB7 transcriptionally more active; poly(ADP-ribosyl)ation altered the DNA-binding activity of HOXB7 (and HOXA7) but not four other tested HOX proteins. Co-immunoprecipitation, GST pull-down, in vitro ADP-ribosylation assay, deletion mutagenesis, luciferase reporter assay, EMSA PloS one High 22844406
2013 The HOXB7/PBX2 dimer acts as a positive transcriptional regulator of oncogenic miR-221 and miR-222 in melanoma; disruption of HOXB7/PBX2 dimers (using the peptide HXR9 that blocks HOX/PBX dimerization) reduces miR-221/222 transcription and elevates c-FOS expression (a direct miR-221/222 target), resulting in cell death. This defines a HOXB7/PBX2→miR-221&222→c-FOS regulatory link. Peptide antagonist (HXR9) treatment, miRNA expression analysis, reporter assay, Western blot, apoptosis assay International journal of cancer Medium 23400877
2014 HOXB7 directly binds and activates the TGFβ2 promoter, as shown by luciferase and ChIP assays. HOXB7-induced migration and invasion were reversed by TGFβ2 knockdown or pharmacological TGFβ signaling inhibition. HOXB7 overexpression also promoted tumor-associated macrophage recruitment and M2 polarization, mediated by TGFβ2, identifying a non-cell-autonomous mechanism of HOXB7-promoted metastasis. ChIP assay, luciferase reporter assay, siRNA knockdown, pharmacological inhibition, in vivo lung metastasis model, macrophage coculture Cancer research High 25542862
2015 HOXB7 physically interacts with ERα (estrogen receptor-α), and the HOXB7-ERα complex enhances transcription of multiple ERα target genes including HER2, as demonstrated by ChIP analysis. MYC, stabilized via EGFR-HER2-mediated phosphorylation, inhibits transcription of miR-196a (a HOXB7 repressor), thereby increasing HOXB7 and ER target gene expression, defining a MYC→miR-196a→HOXB7→ERα-HER2 signaling axis. Chromatin immunoprecipitation (ChIP), co-immunoprecipitation, reporter assay, small-molecule MYC inhibitors, in vivo xenograft regression Cancer discovery High 26180042
2015 HOXB7 binding sites on breast cancer cell chromatin were mapped genome-wide (1,504 sites in BT-474 cells) by ChIP-seq; 17 sites were validated by ChIP-qPCR in multiple cell lines. New direct target genes including CTNND2 and SCGB1D2 were identified based on proximity to HOXB7 binding sites and expression changes. ChIP-seq, ChIP-qPCR, gene expression analysis International journal of cancer Medium 26014856
2015 In mesenchymal stromal/stem cells (MSCs), miR-196a upregulation during aging inversely correlated with HOXB7 expression; forced HOXB7 expression improved cell growth, reduced senescence, and improved osteogenesis linked to increased autocrine bFGF secretion, establishing HOXB7 as a regulator of MSC proliferation and osteogenic differentiation via bFGF. miRNA overexpression, forced HOXB7 expression, proliferation assay, senescence assay, osteogenic differentiation assay, ELISA for bFGF Stem cells Medium 25428821
2016 HoxB7 stimulates ERK1/2 phosphorylation in pancreatic cancer cell protrusions; knockdown of HOXB7 decreased ERK1/2 phosphorylation, reduced peripheral actin structures and cell protrusions, and inhibited cell motility and invasiveness. HOXB7/ERK1/2 signaling selectively activated JNK and HSP27 phosphorylation to promote motility, demonstrating a non-transcriptional cytoplasmic signaling role for HOXB7 in regulating actin dynamics. siRNA knockdown, rescue expression, immunocytochemistry, Western blot (phospho-ERK, phospho-JNK, phospho-HSP27), motility/invasion assay The Journal of biological chemistry Medium 28912272
2016 HOXB7 knockdown in cutaneous squamous cell carcinoma (CSCC) cells inhibited migration and invasion and induced apoptosis via inactivation of the Wnt/β-catenin signaling pathway; co-immunoprecipitation demonstrated that endogenous HOXB7 binds to β-catenin, and HOXB7 regulated expression of downstream Wnt/β-catenin target genes. siRNA knockdown, co-immunoprecipitation, Western blot, transwell assay, xenograft in nude mice American journal of physiology. Cell physiology Medium 30067384
2016 HOXB7 knockdown in colon cancer cells (HoxB7-overexpressing) stimulated DNA repair in a transcription-dependent manner requiring both the transactivation domain and the homeodomain (which mediates KU70/80 interaction), while Cdx2 inhibited DNA repair via a transcription-independent mechanism. In cells co-expressing both proteins, Cdx2 formed a molecular complex with HoxB7 and prevented it from recognizing its chromatin target, reducing HoxB7-driven DNA repair. Co-immunoprecipitation, DNA repair functional assay (etoposide treatment), domain deletion mutagenesis, gain/loss-of-function Cancer letters Medium 26902420
2017 HOXB7 was localized to cell protrusions of migrating pancreatic cancer cells as shown by immunocytochemistry; this cytoplasmic/protrusion localization was functionally linked to actin remodeling and cell motility, as HOXB7 knockdown reduced protrusions and motility, which were restored by rescue expression. Immunocytochemistry, siRNA knockdown, rescue construct transfection, motility assay The Journal of biological chemistry Medium 28912272
2019 HOXB7 interacts with Ku70, Ku80, and DNA-PKcs in esophageal squamous cell carcinoma cells, confirmed by GST pull-down, co-immunoprecipitation, and immunofluorescent colocalization; HOXB7 knockdown reduced Ku70, Ku80, and DNA-PKcs expression and arrested cells in S phase, sensitizing cells to cisplatin. The HOX/PBX dimerization inhibitor HXR9 synergized with cisplatin, providing further functional evidence. GST pull-down, co-immunoprecipitation, immunofluorescent colocalization, siRNA knockdown, Western blot, cisplatin sensitivity assay, HXR9 peptide treatment Thoracic cancer Medium 31568655
2020 HOXB7 and β-catenin formed a functional complex in adipose-derived mesenchymal stem cells (ADMSCs), confirmed by immunoprecipitation; this complex modulated both osteogenesis and adipogenesis. miR-24 targeting of HOXB7 inhibited osteogenesis and promoted adipogenesis, effects partially reversed by HOXB7 overexpression, indicating the miR-24/HOXB7/β-catenin axis controls differentiation balance. Immunoprecipitation, miRNA overexpression/knockdown, luciferase reporter assay, osteogenic/adipogenic differentiation assay, in vivo calvarial defect model FASEB journal Medium 32413244
2023 HOXB7 overexpression in immortalized NMuMG mammary cells induced cellular transformation, tumorigenesis, and lung metastasis through activation of JAK-STAT signaling, identifying JAK-STAT pathway activation as a downstream mechanism of HOXB7-driven malignant transformation. Gain-of-function overexpression in NMuMG cells, transformation assay, in vivo tumorigenesis and metastasis assay, JAK-STAT pathway analysis Genes to cells Medium 36659836
2024 HOXB7 was identified as a key transcriptional regulator of PIGT (GPI transamidase subunit) in hepatocellular carcinoma, with HOXB7-induced PIGT upregulation promoting HCC progression through the Wnt/β-catenin pathway; validated in animal models. JASPAR transcription factor binding prediction, in vivo tumor model validation, gene expression analysis Expert review of anticancer therapy Low 40808272
2024 HOXB7 downregulation using siRNA enhanced HLA class II expression on tumor cells by decreasing MAPK phosphorylation, and MAPK inhibition augmented IFN-γ production by HOXB7-reactive CD4+ T cells, establishing a mechanistic link between HOXB7 expression, MAPK signaling, and tumor immune evasion. siRNA knockdown, Western blot (phospho-MAPK), flow cytometry (HLA-II), T cell cytokine assay, MAPK inhibitor treatment Cancer science Medium 36285482
2021 HOXB7 silencing in TNBC MDA-MB-468 cells reduced DNMT3B expression and decreased methylation of the CDH1 (E-cadherin) promoter, resulting in increased CDH1 expression. ChIP-qPCR in HOXB7-overexpressing cells showed enriched HOXB7 binding at CTNNB1, EGFR, FGF2, CDH1, DNMT3B, TGFB2, and COMMD7 loci, suggesting HOXB7 regulates CDH1 epigenetically via DNMT3B. siRNA knockdown, RT-PCR, Western blot, bisulfite sequencing (promoter methylation), ChIP-qPCR Genes Medium 34680970
2012 The adenovirus early protein E4orf6 was identified as a novel HoxB7-associated protein by yeast two-hybrid screening; HoxB7 knockdown led to inefficient adenoviral progeny production and reduced expression of multiple adenoviral promoters, demonstrating that HoxB7 activates adenoviral gene transcription. Yeast two-hybrid, HoxB7 knockdown cell line, viral replication assay, adenoviral promoter expression analysis Journal of virology Low 22553335
1993 Cis-acting elements controlling A-P restricted Hoxb-7 expression are located within 3.5 kb proximal upstream sequences; deletion analysis revealed at least three cooperating cis-acting control elements. One element conferring Hox-like A-P expression boundaries acts in an orientation- and promoter-dependent manner. Additionally, control sequences of Hoxb-7 map within the 3' UTR of the neighboring Hoxb-8 gene, and Hoxb-7 control sequences modulate Hoxb-8 expression, suggesting cis-regulatory interactions between clustered Hox genes. Transgenic mice, promoter-reporter deletion analysis, in situ hybridization Development Medium 8104144
1998 In Hoxa7/Hoxb7 double-mutant mice, first and second rib defects occurred at higher penetrance and expressivity than in single Hoxb7−/− mutants, demonstrating functional genetic interaction between paralogous Hoxa7 and Hoxb7 genes in patterning the upper thoracic skeleton. Targeted gene disruption (knockout), skeletal analysis of single and double mutant mice Mechanisms of development High 9784603
1998 Culturing mouse mammary epithelial cell lines (SCp2 and CID-9) on a basement membrane that induces a lactational phenotype turned off Hoxb-7 expression, demonstrating that extracellular matrix signaling modulates HOXB7 expression in mammary epithelial cells. Culture on basement membrane vs. inert substratum (polyHEMA), RT-PCR Journal of cellular biochemistry Low 9620166

Source papers

Stage 0 corpus · 94 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2014 P53-regulated long non-coding RNA TUG1 affects cell proliferation in human non-small cell lung cancer, partly through epigenetically regulating HOXB7 expression. Cell death & disease 386 24853421
2006 HOXB7, a homeodomain protein, is overexpressed in breast cancer and confers epithelial-mesenchymal transition. Cancer research 175 17018609
1996 HOXB7 constitutively activates basic fibroblast growth factor in melanomas. Molecular and cellular biology 171 8756643
2001 HOXB7: a key factor for tumor-associated angiogenic switch. Cancer research 120 11522651
2010 MicroRNA miR-196a is a central regulator of HOX-B7 and BMP4 expression in malignant melanoma. Cellular and molecular life sciences : CMLS 113 20480203
2011 The HOXB7 protein renders breast cancer cells resistant to tamoxifen through activation of the EGFR pathway. Proceedings of the National Academy of Sciences of the United States of America 102 21690342
2007 A role for the HOXB7 homeodomain protein in DNA repair. Cancer research 84 17308091
1998 Transduction of the SkBr3 breast carcinoma cell line with the HOXB7 gene induces bFGF expression, increases cell proliferation and reduces growth factor dependence. Oncogene 77 9681827
2015 HOXB7 Is an ERα Cofactor in the Activation of HER2 and Multiple ER Target Genes Leading to Endocrine Resistance. Cancer discovery 73 26180042
2017 miR-196b-5p Regulates Colorectal Cancer Cell Migration and Metastases through Interaction with HOXB7 and GALNT5. Clinical cancer research : an official journal of the American Association for Cancer Research 67 28533224
1998 Analysis of Hoxa7/Hoxb7 mutants suggests periodicity in the generation of the different sets of vertebrae. Mechanisms of development 65 9784603
2008 Hoxb7 inhibits transgenic HER-2/neu-induced mouse mammary tumor onset but promotes progression and lung metastasis. Cancer research 62 18463397
2014 HOXB7 promotes malignant progression by activating the TGFβ signaling pathway. Cancer research 61 25542862
2015 Mesenchymal progenitors aging highlights a miR-196 switch targeting HOXB7 as master regulator of proliferation and osteogenesis. Stem cells (Dayton, Ohio) 59 25428821
1999 Enforced expression of HOXB7 promotes hematopoietic stem cell proliferation and myeloid-restricted progenitor differentiation. Oncogene 58 10208421
2012 HOXB7 promotes invasion and predicts survival in pancreatic adenocarcinoma. Cancer 56 22914903
2013 The abrogation of the HOXB7/PBX2 complex induces apoptosis in melanoma through the miR-221&222-c-FOS pathway. International journal of cancer 55 23400877
1999 CBP and histone deacetylase inhibition enhance the transactivation potential of the HOXB7 homeodomain-containing protein. Oncogene 50 10435624
1993 Proximal cis-acting elements cooperate to set Hoxb-7 (Hox-2.3) expression boundaries in transgenic mice. Development (Cambridge, England) 50 8104144
1998 Expression of Hoxa-1 and Hoxb-7 is regulated by extracellular matrix-dependent signals in mammary epithelial cells. Journal of cellular biochemistry 48 9620166
2010 HOXB7 expression by myeloma cells regulates their pro-angiogenic properties in multiple myeloma patients. Leukemia 45 21183939
2000 HOXB7 overexpression promotes differentiation of C3H10T1/2 cells to smooth muscle cells. Journal of cellular biochemistry 43 10842316
2017 HOXB7 accelerates the malignant progression of hepatocellular carcinoma by promoting stemness and epithelial-mesenchymal transition. Journal of experimental & clinical cancer research : CR 41 28646927
2017 MiR-376c-3p regulates the proliferation, invasion, migration, cell cycle and apoptosis of human oral squamous cancer cells by suppressing HOXB7. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 39 28482289
2001 Identification of novel functional regions important for the activity of HOXB7 in mammalian cells. Journal of immunology (Baltimore, Md. : 1950) 36 11290787
2016 The Widening Sphere of Influence of HOXB7 in Solid Tumors. Cancer research 35 27197229
2015 DNA methylation analysis of Homeobox genes implicates HOXB7 hypomethylation as risk factor for neural tube defects. Epigenetics 35 25565354
2020 LncRNA MAGI2-AS3 Overexpression Sensitizes Esophageal Cancer Cells to Irradiation Through Down-Regulation of HOXB7 via EZH2. Frontiers in cell and developmental biology 33 33330444
2012 Role of HOXB7 in regulation of progression and metastasis of human lung adenocarcinoma. Molecular carcinogenesis 33 22911672
2021 Silencing of hsa_circ_0009035 Suppresses Cervical Cancer Progression and Enhances Radiosensitivity through MicroRNA 889-3p-Dependent Regulation of HOXB7. Molecular and cellular biology 31 33782039
2018 HOXB7 overexpression in lung cancer is a hallmark of acquired stem-like phenotype. Oncogene 31 29576613
2015 Identification of several potential chromatin binding sites of HOXB7 and its downstream target genes in breast cancer. International journal of cancer 31 26014856
2013 HOXB7 mRNA is overexpressed in pancreatic ductal adenocarcinomas and its knockdown induces cell cycle arrest and apoptosis. BMC cancer 31 24088503
2018 Circular RNA hsa_circ_0074362 Promotes Glioma Cell Proliferation, Migration, and Invasion by Attenuating the Inhibition of miR-1236-3p on HOXB7 Expression. DNA and cell biology 30 30388035
2019 HOXB7 mediates cisplatin resistance in esophageal squamous cell carcinoma through involvement of DNA damage repair. Thoracic cancer 29 31568655
2018 Specific knockdown of HOXB7 inhibits cutaneous squamous cell carcinoma cell migration and invasion while inducing apoptosis via the Wnt/β-catenin signaling pathway. American journal of physiology. Cell physiology 26 30067384
1999 IkappaB-alpha enhances transactivation by the HOXB7 homeodomain-containing protein. The Journal of biological chemistry 26 10026139
2016 The roles of HOXB7 in promoting migration, invasion, and anti-apoptosis in gastric cancer. Journal of gastroenterology and hepatology 25 26968988
2014 Levels of HOXB7 and miR-337 in pancreatic ductal adenocarcinoma patients. Diagnostic pathology 25 24641834
2014 miR-337 regulates the proliferation and invasion in pancreatic ductal adenocarcinoma by targeting HOXB7. Diagnostic pathology 25 25183455
2020 CircRNA hsa_circ_0070934 functions as a competitive endogenous RNA to regulate HOXB7 expression by sponging miR‑1236‑3p in cutaneous squamous cell carcinoma. International journal of oncology 24 32626939
2017 The transcription factor HOXB7 regulates ERK kinase activity and thereby stimulates the motility and invasiveness of pancreatic cancer cells. The Journal of biological chemistry 24 28912272
2008 Oncogenic HoxB7 requires TALE cofactors and is inactivated by a dominant-negative Pbx1 mutant in a cell-specific manner. Cancer letters 22 18378073
1998 Regulation of a Purkinje cell-specific promoter by homeodomain proteins: repression by engrailed-2 vs. synergistic activation by Hoxa5 and Hoxb7. Journal of neurobiology 21 9740027
2015 Upregulation of HOXB7 promotes the tumorigenesis and progression of gastric cancer and correlates with clinical characteristics. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 20 26307396
2012 Detection of IGF2BP3, HOXB7, and NEK2 mRNA expression in brush cytology specimens as a new diagnostic tool in patients with biliary strictures. PloS one 20 22879911
1995 Differential effects of retinoic acid and a retinoid antagonist on the spatial distribution of the homeoprotein Hoxb-7 in vertebrate embryos. Developmental dynamics : an official publication of the American Association of Anatomists 19 8601038
2019 MicroRNA-384 is lowly expressed in human prostate cancer cells and has anti-tumor functions by acting on HOXB7. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 18 30951946
2015 HOXB7-S3 inhibits the proliferation and invasion of MCF-7 human breast cancer cells. Molecular medicine reports 18 26135503
2021 Long non-coding RNA SNHG8 promotes prostate cancer progression through repressing miR-384 and up-regulating HOXB7. The journal of gene medicine 17 33450101
2021 HOXB7 acts as an oncogenic biomarker in head and neck squamous cell carcinoma. Cancer cell international 15 34303375
2003 HOXB7 expression is regulated by the transcription factors NF-Y, YY1, Sp1 and USF-1. Biochimica et biophysica acta 15 12697323
2020 Psoralen Suppresses Cisplatin-Mediated Resistance and Induces Apoptosis of Gastric Adenocarcinoma by Disruption of the miR196a-HOXB7-HER2 Axis. Cancer management and research 14 32368152
2012 ADP ribosylation by PARP-1 suppresses HOXB7 transcriptional activity. PloS one 14 22844406
2016 Overexpression of HOXB7 protein reduces sensitivity of oral cancer cells to chemo-radiotherapy. Cancer gene therapy 13 27834359
2021 HOXB7 Overexpression Leads Triple-Negative Breast Cancer Cells to a Less Aggressive Phenotype. Biomedicines 12 34063128
2020 Copy number variation in HOXB7 and HOXB8 involves in the formation of beard trait in chickens. Animal genetics 12 33058257
2019 HOXB7 promotes proliferation and metastasis of glioma by regulating the Wnt/β-catenin pathway. European review for medical and pharmacological sciences 12 30964174
2016 HOXB7 and Hsa-miR-222 as the Potential Therapeutic Candidates for Metastatic Colorectal Cancer. Recent patents on anti-cancer drug discovery 12 27855613
2022 Long non-coding RNA BBOX1-AS1 exacerbates esophageal squamous cell carcinoma development by regulating HOXB7/β-catenin axis. Experimental cell research 11 35351402
2020 MiR-513a-3p inhibits EMT mediated by HOXB7 and promotes sensitivity to cisplatin in ovarian cancer cells. European review for medical and pharmacological sciences 11 33155195
2016 Distinct mechanisms for opposite functions of homeoproteins Cdx2 and HoxB7 in double-strand break DNA repair in colon cancer cells. Cancer letters 10 26902420
2015 A pivotal role for HOXB7 protein in endocrine resistant breast cancer. Oncoscience 10 26697525
2018 Inhibition of HOXB7 suppresses p27-mediated acute lymphoblastic leukemia by regulating basic fibroblast growth factor and ERK1/2. Life sciences 9 30537478
2011 Overexpression of HOXB7 and homeobox genes characterizes multiple myeloma patients lacking the major primary immunoglobulin heavy chain locus translocations. American journal of hematology 9 21953534
2021 Microfragmented adipose tissue is associated with improved ex vivo performance linked to HOXB7 and b-FGF expression. Stem cell research & therapy 8 34454577
2020 The let-7c/HoxB7 axis regulates the cell proliferation, migration and apoptosis in hepatocellular carcinoma. Anti-cancer drugs 8 31609764
2017 Upregulation of HOXB7 promotes proliferation and metastasis of osteosarcoma cells. Molecular medicine reports 8 28677742
2016 HOXB7 as a promising molecular marker for metastasis in cancers: a meta-analysis. OncoTargets and therapy 8 27274269
2015 HoxB7 PROMOTES GROWTH AND METASTASIS OF LUNG ADENOCARCINOMA CELLS THROUGH REGULATION OF THE TGF-β/SMAD3 SIGNALING. Journal of biological regulators and homeostatic agents 8 26403398
1998 Molecular cloning of a mutated HOXB7 cDNA encoding a truncated transactivating homeodomain-containing protein. Journal of cellular biochemistry 8 9736453
2020 The opposite functions of miR-24 in the osteogenesis and adipogenesis of adipose-derived mesenchymal stem cells are mediated by the HOXB7/β-catenin complex. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 7 32413244
2021 Propofol prevents the aggressive progression of oral squamous cell carcinoma via regulating circ_0005623/miR-195-5p/HOXB7 axis. Biotechnology and applied biochemistry 6 33894003
2020 Role of HOXB7 in promoting gastric cancer progression and oxaliplatin (L-OHP) resistance. International journal of clinical and experimental pathology 6 32661473
2023 Circ_0068631 sponges miR-139-5p to promote the growth and metastasis of cutaneous squamous cell carcinoma by upregulating HOXB7. Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI) 5 36823512
2022 Mitogen-activated protein kinase inhibition augments the T cell response against HOXB7-expressing tumor through human leukocyte antigen upregulation. Cancer science 5 36285482
2021 HOXB7 promotes proliferation and metastasis of glioma by regulating the Wnt/β-catenin pathway. European review for medical and pharmacological sciences 5 33928593
2021 Epigenetic Regulation of CDH1 Is Altered after HOXB7-Silencing in MDA-MB-468 Triple-Negative Breast Cancer Cells. Genes 5 34680970
2015 Targeting a Novel ER/HOXB7 Signaling Loop in Tamoxifen-Resistant Breast Cancer. Cancer discovery 5 26334046
2012 Functional cooperation between human adenovirus type 5 early region 4, open reading frame 6 protein, and cellular homeobox protein HoxB7. Journal of virology 5 22553335
2024 Expression of HOXB7 in the Lung of Patients with Idiopathic Pulmonary Fibrosis: A Proof-of-Concept Study. Biomedicines 4 38927528
2016 Immunoexpression of hoxb7 and hoxb9 in salivary gland tumours. Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology 4 26991799
2024 MIR143HG promotes methylation of transcription factor HOXB7 promoter by recruiting methyltransferase DNMT1 to prevent the progression of colon cancer. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 3 38127104
2024 Comprehensive analysis of mesenchymal cells reveals a dysregulated TGF-β/WNT/HOXB7 axis in patients with myelofibrosis. JCI insight 3 39470742
2023 HOXB7 induces STAT3-mediated transformation and lung metastasis in immortalized mammary gland NMuMG cells. Genes to cells : devoted to molecular & cellular mechanisms 3 36659836
2015 Altered response of pendrin-positive intercalated cells in the kidney of Hoxb7-Cre;Mib1f/f mice. Histology and histopathology 3 25594189
2005 Identification of two candidate collecting duct cell-specific cis-acting elements in the Hoxb-7 promoter region. Biochimica et biophysica acta 3 15716052
2024 In Vivo HOXB7 Gene Silencing and Cotreatment with Tamoxifen for Luminal A Breast Cancer Therapy. Pharmaceuticals (Basel, Switzerland) 2 39458966
2024 Thalidomide suppresses migration and invasion of colorectal cancer cells by inhibiting HOXB7-mediated activation of the Wnt/β-catenin signaling pathway. Chemical biology & drug design 1 38230780
2024 Extracellular vesicle-based anti-HOXB7 CD8+ T cell-specific vaccination strengthens antitumor effects induced by vaccination against Her2/neu. Cancer gene therapy 1 39300218
2026 Effect of HOXB7 in promoting proliferation, invasion and migration of cervical cancer cells. Cytotechnology 0 41641288
2025 The transcription factor HOXB7 significantly enhances the expression of PIGT through the Wnt/β-catenin signaling pathway, thereby promoting the proliferation and deterioration of HCC. Expert review of anticancer therapy 0 40808272
2025 Role of c-Myc-regulated miR-196a-5p in the progression of triple-negative breast cancer: Potential involvement of HOXA7 and HOXB7. Mutation research 0 41385964
2001 [Influence of human cytomegalovirus infection on the expression of HOXB5, HOXB6, HOXB7, and HOXB8 genes in gliomaous cells]. Hunan yi ke da xue xue bao = Hunan yike daxue xuebao = Bulletin of Hunan Medical University 0 12536483

Missed literature

Know a paper Affinage missed for HOXB7? Flag it for the maintainers and the community.

No submissions yet.